[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Axsome Thera (AXSM)

Axsome Thera (AXSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,131,046
  • Shares Outstanding, K 51,460
  • Annual Sales, $ 638,500 K
  • Annual Income, $ -183,170 K
  • EBIT $ -167 M
  • EBITDA $ -156 M
  • 60-Month Beta 0.61
  • Price/Sales 20.45
  • Price/Cash Flow N/A
  • Price/Book 239.23

Options Overview Details

View History
  • Implied Volatility 41.12% (-1.15%)
  • Historical Volatility 38.08%
  • IV Percentile 55%
  • IV Rank 22.51%
  • IV High 82.40% on 04/29/26
  • IV Low 29.12% on 01/22/26
  • Expected Move (DTE 5) 9.50 (3.72%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 517
  • Volume Avg (30-Day) 1,320
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 34,501
  • Open Int (30-Day) 31,828
  • Expected Range 245.67 to 264.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.83
  • Number of Estimates 7
  • High Estimate $0.15
  • Low Estimate $-1.60
  • Prior Year $-0.92
  • Growth Rate Est. (year over year) +9.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
217.15 +17.51%
on 06/03/26
257.92 -1.07%
on 06/12/26
+31.14 (+13.90%)
since 05/12/26
3-Month
152.28 +67.57%
on 03/24/26
257.92 -1.07%
on 06/12/26
+101.05 (+65.57%)
since 03/12/26
52-Week
96.09 +165.55%
on 08/04/25
257.92 -1.07%
on 06/12/26
+148.92 (+140.16%)
since 06/12/25

Most Recent Stories

More News
Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive...

AXSM : 255.17 (+0.55%)
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 255.17 (+0.55%)
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,...

AXSM : 255.17 (+0.55%)
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today highlighted...

AXSM : 255.17 (+0.55%)
Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 255.17 (+0.55%)
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 255.17 (+0.55%)
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive disorder,...

AXSM : 255.17 (+0.55%)
Axsome Therapeutics Recognizes Mental Health Month

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 255.17 (+0.55%)
Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 255.17 (+0.55%)
Axsome: Q1 Earnings Snapshot

Axsome: Q1 Earnings Snapshot

AXSM : 255.17 (+0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.

See More

Key Turning Points

3rd Resistance Point 262.60
2nd Resistance Point 260.26
1st Resistance Point 257.72
Last Price 255.17
1st Support Level 252.83
2nd Support Level 250.49
3rd Support Level 247.95

See More

52-Week High 257.92
Last Price 255.17
Fibonacci 61.8% 196.10
Fibonacci 50% 177.01
Fibonacci 38.2% 157.91
52-Week Low 96.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.